Journal
PHARMACOGENOMICS
Volume 17, Issue 2, Pages 103-109Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.155
Keywords
antipsychotic; clinical response; clozapine; DRD2; genetics; pharmacogenetics; schizophrenia
Categories
Funding
- Allon
- Alkermes Bioline
- GlaxoSmithKline Intracellular Therapies
- Lilly
- Merck
- Novartis
- Pfizer
- Pierre Fabre
- Psychogenics
- F Hoffman-La Roche Ltd
- Sunovion
- Targacept
- Abbott Labs
- ACADIA
- Alkemes
- Bristol-Myers Squibb
- Dai-Nippon Sumitomo
- Eli Lilly
- EnVivo
- Janssen
- Otsuka
- Roche
- BiolineRx
- Roche/Genentech
- Lundbeck
- Alkermes
- Brian and Behavior Research Foundation
- American Foundation for Suicide Prevention
Ask authors/readers for more resources
Aim: The recent Psychiatric Genomics Consortium genome-wide association study identified an SNP, rs2514218, located 47kb upstream of the DRD2 gene to be associated with risk for schizophrenia (p = 2.75e-11). Since all antipsychotics bind to dopamine D2 receptors, we examined rs2514218 in relation to response to antipsychotic treatment. Patients & methods: We investigated the SNP in relation to treatment response in a prospective study consisting of 208 patients (151 Caucasians, 42 African-Americans and 15 others) treated with clozapine for 6 months. Results: rs2514218 was associated with total score change in the brief psychiatric rating scale under an additive model (p(corr) = 0.033). Conclusion: Our finding provides evidence for rs2514218 association with antipsychotic response, but further replication is required before firm conclusions can be drawn.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available